Skip to main content
Publications
Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-42. doi: 10.1002/cam4.5308
Paquette M, Franca LR, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Olshansky B, Huisman MV, Lip GYH, Nieuwlaat R. Dabigatran persistence and outcomes following discontinuation in atrial fibrillation patients from the GLORIA-AF registry. Am J Cardiol. 2020 Feb 1;125(3):383-91. doi: 10.1016/j.amjcard.2019.10.047
Lupo PJ, Danysh HE, Plon SE, Curtin K, Malkin D, Hettmer S, Hawkins DS, Skapek SX, Spector LG, Papworth K, Melin B, Erhardt EB, Grufferman S, Schiffman JD. Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. Cancer Med. 2015 May;4(5):781-90. doi: 10.1002/cam4.448
Ribera A, Ferreira-Gonzalez I, Marsal JR, Cascant P, Permanyer-Miralda G, Abdul-Jawad O, Inigo-Garcia LA, Guarinos-Oltra J, Cequier A, Goicolea-Guemez L, Garcia-Del-Blanco B, Marti G, Garcia-Dorado D. Prognostic value of an abnormal ankle-brachial index in patients receiving drug-eluting stents. Am J Cardiol. 2011 Nov 1;108(9):1225-31. doi: 10.1016/j.amjcard.2011.06.036